Articles tagged with Atrial Fibrillation
The ADOPT-A trial demonstrates the effectiveness of the AF Suppression algorithm in reducing symptomatic atrial fibrillation (AF) burden. The study found a significant 25% reduction in symptomatic AF episodes in patients using the algorithm compared to those with standard pacemaker indications.
Researchers discovered that one out of six patients with a history of atrial fibrillation had asymptomatic episodes, highlighting the need for regular blood thinning to prevent stroke. The study suggests doctors should assume the worst when treating patients at risk of atrial fibrillation and stroke.
The SPORTIF III study demonstrates Exanta's efficacy in preventing stroke and systemic embolic events, with a 41% reduced risk of major bleeding events compared to warfarin. The fixed-dose oral medication offers a convenient alternative to traditional treatment, eliminating the need for coagulation monitoring and dietary restrictions.
Researchers have identified the KCNQ1 gene as the primary cause of familial atrial fibrillation, a condition affecting nearly one in 20 individuals over 65. The mutation leads to excessive potassium channel activity, disrupting normal heart rhythms and increasing the risk of heart failure.
The study found that controlling heart rate provides no benefit over controlling the heart's irregular rhythm in patients with atrial fibrillation. This approach may also be less expensive due to lower hospitalization rates and costs.
Researchers at the Mayo Clinic document a safer treatment approach for atrial fibrillation, utilizing adequate anticoagulation medication to reduce the risk of stroke and thromboembolism. The study, conducted from 1990-1994, involved 834 successful cardioversions performed in 717 patients, with an incidence rate of less than 1%.
Researchers found that combining irbesartan with amiodarone significantly reduced the likelihood of recurring atrial fibrillation. The study involved 154 patients and showed a nearly 85% probability of maintaining a stable heartbeat for those treated with irbesartan, compared to 63% for those without.
Researchers at Penn find a cure for atrial fibrillation by targeting triggers in pulmonary veins, eliminating the need for pacemakers and medication. The new procedure has shown effectiveness and low complication rates, offering hope for patients with this serious condition.
Exanta shows comparable efficacy to warfarin in preventing stroke in patients with atrial fibrillation, with the added benefit of no dose titration or routine coagulation monitoring. The THRIVE programme also highlights Exanta's promise in treating venous thromboembolism.
A recent study published in the New England Journal of Medicine found that warfarin and aspirin provide no significant difference in preventing another stroke in ischemic stroke patients without atrial fibrillation. The study, which followed 2,206 individuals for two years, showed no statistically significant differences between the tw...
A 7-year clinical trial comparing aspirin and warfarin found that both drugs are safe and effective in preventing recurrent strokes in most patients. Aspirin slows clotting of blood platelets, while warfarin inhibits circulating clotting proteins.
Researchers have developed a new treatment option for atrial fibrillation using bipolar radiofrequency, which shows promising results in treating the condition. The procedure can be done without using the heart-lung machine and has been tested on sheep with successful outcomes, indicating it may be safe for human patients.
Exanta demonstrated improved safety and tolerability compared to warfarin in treating patients with medium to high risk for stroke and systemic embolism. The phase III SPORTIF programme enrolled over 6,200 patients and showed promising results. Exanta is being investigated as a simpler alternative to warfarin treatment.
A new study has found that frail and elderly patients with chronic atrial fibrillation are less likely to receive stroke-preventing drugs. Warfarin lowers the risk of stroke, heart attack or death by one-fourth in this population, but underuse is common.
A new treatment approach has been developed to restore normal heart rhythms in patients with atrial fibrillation, a condition affecting over 2 million adults. Ibutilide fumarate injection prior to an electrical shock to the heart was successful in converting abnormal rhythms to normal in all study patients.
Researchers have successfully tested an implantable device called Atrioverter to treat atrial fibrillation, a condition that can lead to stroke. The device restored normal rhythm in 96% of treated individuals, offering a new treatment option for those prone to irregular heartbeats.
A Cedars-Sinai Medical Center clinical trial may offer a permanent, non-surgical cure for patients with Paroxysmal Atrial Fibrillation. Correctly identifying patients and eliminating trigger areas using radiofrequency energy could eliminate the need for long-term therapy and reduce stroke risk.
A new study found that low-risk atrial fibrillation patients who take aspirin have a lower risk of stroke compared to those on warfarin, with fewer bleeding complications. The study identified hundreds of thousands of Americans eligible for aspirin therapy and provides new insights into stroke prevention.
Despite evidence of warfarin's effectiveness, it remains underused to prevent strokes in those with atrial fibrillation. The study found that increased prescriptions from 13% to 40% between 1989 and 1993 did not lead to significant changes in usage from 1993 onwards.
A study conducted at the University of Michigan Health System found that administering amiodarone prior to elective heart surgery reduced atrial fibrillation by approximately 50%. Patients who received amiodarone experienced less discomfort, shorter hospital stays, and lower hospital costs compared to those who received a placebo.
The University of Maryland Medical Center has successfully implanted a new device that can regulate a dangerously rapid heartbeat automatically and internally. The Metrix System TM delivers a small electrical shock to the heart, making it a more comfortable alternative to external shocks.
A recent study by American Heart Association found that risk of stroke after heart attack is highest within five days. The research highlights atrial fibrillation and ST elevation as key factors increasing likelihood of a heart attack-related stroke.